NCT00700115View on ClinicalTrials.gov

Kaletra-isentress Treatment Evaluation

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
HIV Infections
Interventions
DRUG

Kaletra + Isentress

Kaletra 400/100 mg + Isentress 400 mg BID

DRUG

Pre-study antiretroviral regimen

Standard doses of pre-study antiretroviral regimen

Trial Locations (1)

30308

Grady Infectious Diseases Program (Ponce Clinic), Atlanta

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Emory University

OTHER